



## US Money Markets

# Federal Reserve Liquidity Programs

The Fed continues to provide more details of its credit programs. We have updated information regarding the Fed's Main Street Lending programs for small and mid-sized businesses. We briefly outline the decision to use Libor in this program and describe the Alternative Reference Rate Committee's (ARRC) recommended fallback language in Figure 9. We have also included a table of the borrower restrictions created under the CARES Act.

As more details become available and we get more information on program usage, we will continue updating our summary sheet.

### Barclays Research

*Fed 'Adjusts' Main Street Lending Facilities to include more leveraged finance issuers, April 30, 2020.*

Joseph Abate  
+1 212 412 7459  
joseph.abate@barclays.com  
BCI, US

[www.barclays.com](http://www.barclays.com)

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report.

**PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES STARTING AFTER PAGE 10**

FIGURE 1

**Eligible central banks (by country)**

UK
Japan
Canada
ECB
Switzerland
Australia
Brazil
Denmark
Korea
Mexico
New Zealand
Singapore
Sweden

Source: Federal Reserve

FIGURE 2

**Primary Dealers**

Amherst Pierpont Securities LLC
Bank of Nova Scotia, New York Agency
BMO Capital Markets Corp.
BNP Paribas Securities Corp.
Barclays Capital Inc.
BofA Securities, Inc.
Cantor Fitzgerald & Co.
Citigroup Global Markets Inc.
Credit Suisse AG, New York Branch
Daiwa Capital Markets America Inc.
Deutsche Bank Securities Inc.
Goldman Sachs & Co. LLC
HSBC Securities (USA) Inc.
Jefferies LLC
J.P. Morgan Securities LLC
Mizuho Securities USA LLC
Morgan Stanley & Co. LLC
NatWest Markets Securities Inc.
Nomura Securities International, Inc.
RBC Capital Markets, LLC
Societe Generale, New York Branch
TD Securities (USA) LLC
UBS Securities LLC.
Wells Fargo Securities, LLC

Source: Federal Reserve

FIGURE 3  
Federal Reserve liquidity programs

Program	Rate (bp)	Operation Frequency	Term	Size	Counterparty	Collateral	Termination	Outstandings (\$bn)	Description
Central bank swap lines	OIS+25	Daily and weekly	1w or 84d	Depends on the central bank	Central banks <sup>1</sup>	Local currency collateral and loans	None <sup>2</sup>	\$410 (Apr 22)	Non-US banks can source \$ funding from their local central bank, which in turn gets it from the Fed
Discount window	Primary credit rate (25bp)	Daily	o/n to 90d	Depends on how much collateral is pledged	Banks	a) Loans and investment grade securities b) No equities	None <sup>2</sup>	\$32(Apr 22)	Traditional lender of last resort program for banks
<a href="#">CP funding facility (CPFF)</a>	a) 3m OIS +110 b) 10bp one time registration fee	Daily	3m	Issuer is limited to the maximum of its outstandings between March 2019 and March 2020	A1/P1 issuers <sup>3</sup>	None	17-Mar-21	\$3bn (Apr 22)	a) Fed buys the issuer's CP and holds it to maturity; issuer receives cash b) Treasury is providing \$10bn equity investment in the CPFF SPV for loss protection to the Fed
<a href="#">Primary dealer credit facility (PDCF)</a>	25	Daily	o/n to 90d Prepayments allowed	Depends on how much acceptable collateral the dealer pledges	Primary dealers <sup>4</sup>	IG corporate debt CP (A2/P2) Munis ABS, MBS Equities	At least 6m and possibly longer if conditions warrant	\$32 (Apr 22)	a) Dealers pledge illiquid collateral in return for cash b) Recourse loan (beyond collateral value) to the primary dealer
<a href="#">Money market liquidity facility (MMLF)</a>	a) primary credit +100bp for assets from prime funds b) primary credit+25bp for assets from muni funds	Daily	Maturity matches the maturity of the pledged paper	Depends on how much acceptable collateral the bank pledges	Banks	a) Prime MMF assets Including A1/P1 CP and AB-CP, along with certain non-TSY/AGY repo	30-Sep-20	\$49 (Apr 22)	a) Banks buy prime fund assets, which they pledge to the Fed in return for cash that they give to the prime fund b) Non-recourse loan to banks, so these assets are excluded from the leverage and RWA capital ratios
FIMA Repo facility	IOER+25bp	as needed	overnight	Depends on how much acceptable collateral the central bank pledges	Central banks and monetary authorities	Treasuries only	at least 6m	\$0 (Apr 22)	Foreign central banks can repo Treasuries to the Fed in return for dollar funding

Program	Rate (bp)	Operation Frequency	Term	Size	Counterparty	Collateral	Termination	Outstandings (\$bn)	Description
Open market operations	variable	Multiple times per day	overnight 1w, 2w, 1m, 3m	Depends on how much acceptable collateral the dealer pledges	Primary dealers	Treasuries and MBS	As long as necessary, although weakening demand may lead to some program trimming	\$157 (Apr 27)	Temporary financing of collateral and reserve expansion

<sup>1</sup> See Figure 1.

<sup>2</sup> No termination for the regular operations of these programs

<sup>3</sup> Issuers that were rated A1/P1 on March 17, 2020, but are subsequently downgraded will be able to sell their paper (once) to the Fed. These issuers will pay a higher rate of OIS+200.

<sup>4</sup> See Figure 2.

Source: Federal Reserve, Barclays Research

FIGURE 4  
Credit market programs

Program	Rate (bp)	Operation Frequency	Term	Fees	Size	Counterparty	Collateral	Termination	Description
<a href="#">Main Street lending programs</a>	Libor+300bp	as needed	4y loan	a) Eligible lender pays a transaction fee to the Fed on the principal amount of the loan (this can be passed to the borrower); b) The Fed will pay the lender a 25bp servicing fee on the amount of its participation	600bn	US banks and bank holding companies	See Table 8	30-Sep-20	Fed will provide funding to banks so that they can make small business loans
<a href="#">Paycheck Protection Program Liquidity Facility (PPPLF)</a>	35bp	as needed	a) Fed loan matches the maturity of the bank's PPP loans, which are 2y; b) PPP loans have a 0 risk weighting and no effect on the bank's leverage ratio; c) there is no haircut; the Fed will lend the bank the full amount of the PPP loan	None	600bn	a) US Banks, non-depository institutions and financial technology firms	Paycheck Protection Program loans guaranteed by the Small Business Administration		Fed will provide funding collateralized with PPP loans that are backstopped by the SBA.
<a href="#">Term Asset-backed Lending Facility (TALF)</a>	2y Libor swap+100bp1 3y Libor swap+100bp2	as needed	3y loan	a) 10bp administration fee; b) Published collateral haircut schedule	100bn	All US companies with eligible ABS collateral	a) New ABS issued after March 23, except for legacy CMBs b) CLOs, CMBs have been added; c) Credit exposures underlying the ABS must be originated all (or substantially) by US companies; d) SBA pool certificates and development company participation certificates	30-Sep-20	a) US companies will be able to borrow 3y money from the Fed collateralized with newly issued ABS; b) Loans provided are non-recourse to the borrower; c) Treasury will make a \$10bn equity investment in the TALF SPV
<a href="#">Primary Market Corporate Credit Facility (PMCCF)4</a>	Fed will purchase paper from the issuer at a market rate	as needed	up to 4y	100bp facility fee	500bn	US companies	a) New issue corporate debt rated BBB-/Baa3 or higher; b) Lower rated debt (to BB-) is eligible if the borrower is subsequently downgraded; c) Syndicated loans and bonds are eligible; d) the Fed will not buy more than 25% of any syndicated bond or loan e) insured depository institution debt is excluded	30-Sep-20	a) The Fed will buy newly issued corp bond directly from the issuer; b) Recourse to the issuer; c) Treasury will make a \$50bn equity investment in the PMCCF SPV d) Treasury's investment will be leveraged 10:1 for IG debt and 7:1 for <IG

Program	Rate (bp)	Operation Frequency	Term	Fees	Size	Counterparty	Collateral	Termination	Description
<a href="#">Secondary Market Corporate Credit Facility (SMCCF)</a> <sup>4</sup>	market price	Initially purchases will be through primary dealers	up to 5y	None	250	US companies	a) Investment grade corporate bonds with remaining maturities of less than 5y; b) US listed ETFs with exposure to investment grade and high yield corporates; c) insured depository debt is excluded	30-Sep-20	a) The Fed will buy eligible corporate bonds and ETFs from the secondary market; b) Treasury will make a \$25bn equity investment in the SMCCF SPV; c) Treasury's investment will be leveraged 10:1 for IG, 7:1 for <IG, and between 3-7:1 for ETFs, depending on the risk
<a href="#">Municipal Liquidity Facility</a>	a) Fed will purchase paper from the issuer; b) no details yet on program rate	as needed	up to 36m	10bp origination fee based on the principal amount	500bn	a) States and counties with at least 500,000 residents, Cities with at least 250,000 residents; b) Counterparty size limit set at 20% of general revenue from own sources as of FY 2017	a) Tax anticipation notes, tax and revenue anticipation notes, bond anticipation notes, as well as other short-term debt; b) debt must be BBB-/Baa3 as of April 8. The Fed will buy subsequently downgraded issuers' paper provided it is at least BB-/Ba3	30-Sep-20	a) Fed will buy short-term municipal debt from issuers; b) the Treasury will provide a \$35bn equity investment into the Municipal Liquidity Facility SPV

1 If the WAL of the ABS is less than 2y

2 If the WAL of the ABS is greater than 2y

3 See Figure 6

4 For more details see Figure 7

5 The Fed will add eligible counterparties over time. Counterparties must US based companies with a majority of US employees.

Source: Federal Reserve, Barclays Research

FIGURE 5

**Eligible asset-backed paper**

Auto loans and leases.

Student loans.

Credit card receivables (both consumer and corporate).

Equipment loans.

Floorplan loans.

Insurance premium finance loans.

Certain small business loans that are guaranteed by the Small Business Administration.

Eligible servicing advance receivables.

Source: Federal Reserve

FIGURE 6

**Maximum program size, Treasury contribution, and disclosure rules (\$bn)**

Program	Potential	Treasury			
	Max size	Contribution	Launched	Termination	30d disclosure <sup>1</sup>
PMCCF	500	50	-	9/30/2020	yes
SMCCF	250	25	-	9/30/2020	yes
TALF	100	10	-	9/30/2020	yes
Muni Liquidity	500	35	-	12/31/2020	yes
Main Street programs	600	75	-	9/30/2020	yes
PPPLF <sup>3</sup>	600	600	16-Apr	9/30/2020	yes
CPFF	200	10	14-Apr	3/17/2021	yes <sup>2</sup>
MMLF	50	10	20-Mar	9/30/2020	yes <sup>2</sup>
Discount window	None <sup>4</sup>	0	16-Mar	none	no
PDCF	None <sup>4</sup>	0	30-Mar	"at least 6m"/ Sep 2020	no
CB swap lines	None <sup>4</sup>	0	16-Mar	none	no

<sup>1</sup> The Fed will provide a report every 30d on the 13(3) program's balance, interest and fees collected, and expected losses. It recently announced that it will provide additional details for programs created through the CARES Act. This additional information will include the names and details of program participants, along with the amounts borrowed and the respective interest rate.

<sup>2</sup> The initial 30d report, published on April 23, did not contain detailed information on program participants and borrowers.

<sup>3</sup> The Paycheck Protection Plan was created under Sec 1102 of the CARES Act.

<sup>4</sup> Maximum size is determined by the amount of collateral pledged by the counterparty

Source: Federal Reserve, Barclays Research

FIGURE 7

**Additional PMCCF and SMCCF details****PMCCF:**

- The Fed will buy qualifying bonds or loans as a single investor or as part of a syndicate.
- The debt must be investment grade as of March 22, 2020, and rated by at least two NRSROs, if available.
- Issuer must satisfy Section 4019 of the CARES Act on conflicts of interest (no Congressmembers or the immediate family and in-laws of the president and vice president).

- PMCCF debt sold to the Fed can be used to refinance existing debt up to 3m ahead of that debt's maturity. Subject to approval from the Fed.
- PMCCF will only buy fixed rate debt if the Fed is the sole buyer. If the Fed is participating in a syndicate, it can buy floating rate debt. Libor instruments must have adequate fallbacks.
- If the Fed is participating in a syndicated loan or bond as part of the PMCCF, it will pay the same price as the other members. The facility fee applies to the amount the Fed purchases.
- The maximum amount of bonds an issuer can have from the PMCCF cannot exceed 130% of the maximum amount outstanding at any time between March 22, 2019, and March 22, 2020.
- The Fed has a single name concentration limit across the PMCCF and the SMCCF of 1.5% of the SPV capacity.

#### SMCCF:

- The Fed will not buy more than 10% of the issuer's maximum outstanding amount on any day between March 22, 2019, and March 22, 2020.
- The ETF purchases will be limited; it will not buy shares if after the purchase it would hold more than 20% of the outstanding shares.
- The Fed will buy shares from high yield ETFs. However, the "preponderance" of its ETF purchases will be from investment grade funds.
- The SMCCF will buy floating rate debt, including Libor instruments. Given the maturity of eligible SMCCF paper (up to 5y), we assume Libor-based debt will require adequate fallback language (see Figure 8 for a description of the recommended language).
- The Fed plans publicly to disclose PMCCF and SMCCF data during the life of the program. This will include: participants, transactions, costs, revenues and fees. This makes both programs somewhat different than the CPFF.

---

FIGURE 8

#### Main Street Lending Program details

- The Fed has created three loan programs designed to help small and medium-sized business. As these programs are loans, they are not forgivable; they must be paid back
- The three programs: Main Street New Loan Facility (MSNLF), Main Street Priority Loan Facility (MSPLF), and the Main Street Expanded Loan Facility (MSELF). The MSNLF and the MSPLF are for new loans. The MSELF allows a borrower to increase an existing term loan or revolving credit facility.
- The MSNLF and the MSPLF charge the lender a 100bp transaction fee. The lender can pass this onto the borrower. The lender has discretion over when and whether to do so.
- The MELF charges the lender a 75bp fee for the upsized amount of the loan. The lender has similar discretion with respect to when and whether to pass this fee on to the borrower
- Common features across all 3 programs
  - Loans can be secured or unsecured
  - Loans are for 4y and can be pre-paid without penalty



- All program rates are Libor+300bp. The Fed shifted this to Libor from SOFR for expediency, as requiring banks to issue loans off of the new benchmark might be cumbersome and delay getting cash to small and mid-sized businesses. The Libor terms in these loans, however, must include the ARRC recommended fall-back language, as the loans will still be outstanding after Libor publication ceases at the end of 2021.
  - Loans must have trigger clauses that allow for the permanent cessation of Libor publication, as well as pre-cessation clauses based on Libor “un-representativeness”
  - The replacement rate waterfall uses forward term SOFR if it is available; otherwise, it rolls down to compounded SOFR in arrears
  - The spread adjustment recommended by ARRC is the 5y median spread between Libor and SOFR
  - Business loans can be hardwired or amended. Hardwiring sets the replacement rate and spread adjustment in advance. In the amendment approach, both are left to a future date, with a borrower objection right
- All payments are deferred for the first year of the loan
- Eligible firms may have up to 15,000 employees or \$5bn in annual 2019 revenue. Employees and revenue apply across all affiliates
  - Financial and insurance companies are excluded. Non-US companies are also excluded, as well as any company participating in the PMCCF
- Borrowing from the Treasury’s PPP does not exclude the firm from participating in any of the three Main Street programs
- Lenders will apply their own underwriting standards on these loans. As a result, an eligible borrower may receive less (or no) money than the maximum allowable
- The retained portion of these loans are subject to 100% risk weighting for a corporate exposure.
- All Main Street Loan participants are subject to the CARES Act restrictions 4003(c)(3)(A)ii (see Table 9)

	Min. loan Size	Max. Loan Size (lesser of)	Payment Amortization (%) (Years 2-4)	Bank Retention (%)
MSNLF	\$500,000	25m or 4x 2019 EBITDA	33.3% each year	5
MSPLF	\$500,000	25m or 6x 2019 EBITDA	15, 15, 70	15
MSELF	\$10m	200m or 35% of undrawn available debt or 6x 2019 EBITDA	15, 15, 70	5

FIGURE 9

**CARES Act 4003(c)(3)(A)(ii) Limits on Borrower activity**

1. Eligible businesses are those for whom credit is not reasonably available
2. The loan is sufficiently secured or made at a rate that reflects the risk of the loan
3. Loans are made at the shortest maturities possible – up to 5y
4. The eligible business and its affiliates may not buy back shares (of the business or its parent) for the length of the loan plus 12m
5. The eligible business cannot pay dividends or make capital distributions for the length of the loan plus 12m
6. Must maintain its employment levels as of March 24, 2020, through September 30, 2020. And it cannot reduce them by more than 10% on September 30, 2020
7. Mid-sized businesses have similar restrictions

### Analyst Certification

I, Joseph Abate, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

### Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

### Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to <https://publicresearch.barclays.com> or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise. In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <https://publicresearch.barcap.com/S/RD.htm>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <https://publicresearch.barcap.com/S/CM.htm>.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

### Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

### Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to <https://live.barcap.com/go/research/Recommendations>.

### Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)  
Barclays Capital Inc. (BCI, US)  
Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)  
Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)  
Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)  
Barclays Securities Japan Limited (BSJL, Japan)  
Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)  
Barclays Capital Canada Inc. (BCCI, Canada)  
Barclays Bank Mexico, S.A. (BBMX, Mexico)  
Barclays Securities (India) Private Limited (BSIPL, India)  
Barclays Bank PLC, India branch (Barclays Bank, India)  
Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)  
Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

### Disclaimer:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one

or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting [debtresearch@barclays.com](mailto:debtresearch@barclays.com). Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ("Third-Party Content"). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

**United Kingdom:** This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

**European Economic Area ("EEA"):** This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

**Americas:** The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC ([www.iiroc.ca](http://www.iiroc.ca)), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has not filed this material with any regulatory body in those jurisdictions.

**Japan:** This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokuchō (kinsho) No. 143.

**Asia Pacific (excluding Japan):** Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585;

Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC or one of the Barclays group entities. None of Barclays Bank PLC, nor such Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

**Middle East:** Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

**Russia:** This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

**IRS Circular 230 Prepared Materials Disclaimer:** Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

